# 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

> **NCT05480761** · PHASE4 · TERMINATED · sponsor: **QOL Medical, LLC** · enrollment: 312 (actual)

## Conditions studied

- Congenital Sucrase-Isomaltase Deficiency
- CSID
- Sucrase Isomaltase Deficiency

## Interventions

- **BIOLOGICAL:** Sucraid (sacrosidase) Oral Solution 8500 IU/mL

## Key facts

- **NCT ID:** NCT05480761
- **Lead sponsor:** QOL Medical, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-01
- **Primary completion:** 2024-09-18
- **Final completion:** 2024-09-18
- **Target enrollment:** 312 (ACTUAL)
- **Why stopped:** Lack of subject enrollment
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05480761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05480761, "7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05480761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*